DEDUCT | Database of Endocrine Disrupting chemicals and their Toxicity profiles

Padimate-O

No ToxCast endpoints for intended target type: RNA

ToxCast endpoints for intended target type: Protein

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
CCTE_Deisenroth_AIME_96WELL_LUC_Inactive	Mammary gland/breast	Human	2099	ESR1	Gain	16.21 μM
ATG_AP_1_CIS	Liver	Human	2353\|3725	FOS\|JUN	Activatory	61.61 μM
ATG_BRE_CIS	Liver	Human	4086	SMAD1	Activatory	48.95 μM
ATG_DR4_LXR_CIS	Liver	Human	7376\|10062	NR1H2\|NR1H3	Activatory	62.57 μM
ATG_ERE_CIS	Liver	Human	2099	ESR1	Activatory	9.36 μM
ATG_NRF2_ARE_CIS	Liver	Human	4780	NFE2L2	Activatory	27.14 μM
ATG_PPRE_CIS	Liver	Human	5465\|5467\|5468	PPARA\|PPARD\|PPARG	Inhibitory	31.96 μM
ATG_PXRE_CIS	Liver	Human	8856	NR1I2	Inhibitory	8.25 μM
ATG_ERa_TRANS	Liver	Human	2099	ESR1	Gain	5.75 μM
ATG_PPARg_TRANS	Liver	Human	5468	PPARG	Gain	30.29 μM
ATG_PXR_TRANS	Liver	Human	8856	NR1I2	Gain	35.52 μM
TOX21_TR_LUC_GH3_Antagonist	Pituitary gland	Rat	7067\|7068	THRA\|THRB	Loss	37.51 μM
TOX21_p450_CYP2C19_Antagonist		Human	1557	CYP2C19	Loss	9.44 μM
TOX21_p450_CYP2C9_Antagonist		Human	1559	CYP2C9	Loss	13.31 μM
TOX21_p450_CYP1A2_Antagonist		Human	1544	CYP1A2	Loss	4.99 μM
TOX21_CAR_LUC_Agonist	Liver	Human	9970	NR1I3	Gain	35.1 μM
TOX21_p450_CYP2D6_Antagonist		Human	1565	CYP2D6	Loss	57.71 μM
TOX21_p450_CYP2C19_Antagonist		Human	1557	CYP2C19	Loss	13.98 μM
TOX21_p450_CYP2C9_Antagonist		Human	1559	CYP2C9	Loss	13.57 μM
TOX21_p450_CYP1A2_Antagonist		Human	1544	CYP1A2	Loss	5.85 μM
TOX21_hERG_U2OS_Antagonist	Bone	Human	3757	KCNH2	Loss	16.08 μM
TOX21_ARE_KS_LUC_Agonist	Skin	Human	4780	NFE2L2	Gain	40.12 μM
TOX21_AhR_LUC_Agonist	Liver	Human	196	AHR	Gain	41.74 μM
TOX21_CAR_LUC_Agonist	Liver	Human	9970	NR1I3	Gain	46.18 μM
TOX21_PR_BLA_Antagonist_ratio	Kidney	Human	5241	PGR	Loss	32.21 μM
TOX21_PXR_LUC_Agonist	Liver	Human	8856	NR1I2	Gain	34.1 μM
TOX21_p450_CYP2D6_Antagonist		Human	1565	CYP2D6	Loss	40.93 μM
TOX21_p450_CYP2C19_Antagonist		Human	1557	CYP2C19	Loss	13.13 μM
TOX21_p450_CYP2C9_Antagonist		Human	1559	CYP2C9	Loss	15.18 μM
TOX21_p450_CYP1A2_Antagonist		Human	1544	CYP1A2	Loss	4.85 μM

ToxCast endpoints for intended target type: Molecular messenger

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
CEETOX_H295R_OHPREG	Adrenal gland	Human	5241	PGR	Activatory	6.35 μM
CEETOX_H295R_OHPROG	Adrenal gland	Human	5241	PGR	Activatory	8.59 μM
CEETOX_H295R_ANDR	Adrenal gland	Human	367	AR	Activatory	6.13 μM
CEETOX_H295R_DOC	Adrenal gland	Human	2908\|4306	NR3C1\|NR3C2	Inhibitory	6.74 μM
CEETOX_H295R_PROG	Adrenal gland	Human	5241	PGR	Inhibitory	6.01 μM

ToxCast endpoints for intended target type: Pathway

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
OT_AR_ARSRC1_0960	Kidney	Human	367\|6714	AR\|SRC	Gain	70.14 μM
OT_FXR_FXRSRC1_0480	Kidney	Human	6714\|9971	SRC\|NR1H4	Gain	32.68 μM
OT_FXR_FXRSRC1_1440	Kidney	Human	6714\|9971	SRC\|NR1H4	Gain	50.0 μM
OT_NURR1_NURR1RXRa_0480	Kidney	Human	4929\|6256	NR4A2\|RXRA	Gain	77.72 μM
OT_NURR1_NURR1RXRa_1440	Kidney	Human	4929\|6256	NR4A2\|RXRA	Gain	75.95 μM

No ToxCast endpoints for intended target type: Cellular

No ToxCast endpoints for intended target type: Hormone

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.